Omni Bio Pharmaceutical (OTCMKTS:OMBP) vs. Momenta Pharmaceuticals (OTCMKTS:MNTA) Financial Analysis

Share on StockTwits

Omni Bio Pharmaceutical (OTCMKTS:OMBP) and Momenta Pharmaceuticals (NASDAQ:MNTA) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, valuation, earnings, profitability, analyst recommendations, dividends and risk.

Earnings & Valuation

This table compares Omni Bio Pharmaceutical and Momenta Pharmaceuticals’ revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Omni Bio Pharmaceutical N/A N/A N/A N/A N/A
Momenta Pharmaceuticals $75.59 million 15.63 -$176.06 million ($2.03) -5.90

Omni Bio Pharmaceutical has higher earnings, but lower revenue than Momenta Pharmaceuticals.

Insider & Institutional Ownership

97.5% of Momenta Pharmaceuticals shares are held by institutional investors. 3.4% of Momenta Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Risk & Volatility

Omni Bio Pharmaceutical has a beta of 2.5, suggesting that its stock price is 150% more volatile than the S&P 500. Comparatively, Momenta Pharmaceuticals has a beta of 2.19, suggesting that its stock price is 119% more volatile than the S&P 500.

Profitability

This table compares Omni Bio Pharmaceutical and Momenta Pharmaceuticals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Omni Bio Pharmaceutical N/A N/A N/A
Momenta Pharmaceuticals -231.49% -43.98% -33.82%

Analyst Ratings

This is a breakdown of recent recommendations and price targets for Omni Bio Pharmaceutical and Momenta Pharmaceuticals, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Omni Bio Pharmaceutical 0 0 0 0 N/A
Momenta Pharmaceuticals 0 3 2 0 2.40

Momenta Pharmaceuticals has a consensus target price of $23.54, suggesting a potential upside of 96.47%. Given Momenta Pharmaceuticals’ higher probable upside, analysts clearly believe Momenta Pharmaceuticals is more favorable than Omni Bio Pharmaceutical.

Summary

Momenta Pharmaceuticals beats Omni Bio Pharmaceutical on 5 of the 9 factors compared between the two stocks.

About Omni Bio Pharmaceutical

Omni Bio Pharmaceutical, Inc. operates as a biopharmaceutical company in the United States. It holds a license to use patent for the treatment of diabetes using plasma-derived alpha-1 antitrypsin (p-AAT), a protein that is purified from human blood. The company also holds licenses for the use of patents and patent applications covering the use of p-AAT in the treatment of cellular transplantation and graft rejection, radiation protection, bacterial and viral diseases, myocardial remodeling, and inflammatory bowel disease indications. In addition, it holds licenses for patent applications covering compositions of various Fc-AAT constructs. Omni Bio Pharmaceutical, Inc. was founded in 2006 and is headquartered in Fort Collins, Colorado.

About Momenta Pharmaceuticals

Momenta Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery and development of novel biologic therapies for the treatment of rare immune-mediated diseases in the United States. Its novel therapeutic programs include M281, a fully-human anti-neonatal Fc receptor (FcRn), aglycosylated immunoglobulin G (IgG1), and monoclonal antibody to reduce circulating IgG antibodies by blocking endogenous IgG recycling via FcRn; M230, a recombinant trivalent human IgG1 Fc multimer containing three IgG Fc regions joined to maximize activity; and M254, a hyper-sialylated immunoglobulin to treat various inflammatory diseases, including idiopathic thrombocytopenic purpura and chronic inflammatory demyelinating polyneuropathy. The company's biosimilar programs comprise M923, a biosimilar of HUMIRA for the treatment of patients with rheumatoid arthritis, crohn's disease, ulcerative colitis, and psoriasis; and M710, a biosimilar of EYLEA for the treatment of neovascular age-related macular degeneration, macular edema following retinal vein occlusion, diabetic macular edema (DME), and diabetic retinopathy in patients with DME. Its complex generics programs include Enoxaparin sodium injection, a generic version of LOVENOX that is indicated for the prevention and treatment of deep vein thrombosis, as well as supports the treatment of acute coronary syndromes; GLATOPA, a generic version of once-daily COPAXONE for the treatment of patients with relapsing forms of multiple sclerosis; and GLATOPA, a generic version of three-times-weekly COPAXONE. The company has collaboration and license agreements with Sandoz AG, Mylan Ireland Limited, and CSL Behring Recombinant Facility AG. The company was formerly known as Mimeon, Inc. and changed its name to Momenta Pharmaceuticals, Inc. in September 2002. Momenta Pharmaceuticals, Inc. was founded in 2001 and is headquartered in Cambridge, Massachusetts.

Receive News & Ratings for Omni Bio Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omni Bio Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.